{
  "documentMetadata": {
    "title": "Septic Arthritis, Gram-Negative Bacilli",
    "lastUpdated": "2023-09-25",
    "sourceFile": "Arthritis, Septic, Gram-Negative Bacilli.pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Acute inflammatory mono-articular arthritis in adults",
        "Over 5 yr period, 25% of cases of septic arthritis were due to gram-negative bacilli (J Microbiol, Immunol. and Infection 2017;50:527)",
        "Usually result of haematogenous seeding.",
        "Can occur as result of a bite, post-trauma, infected surgical site,or contiguous spread from adjacent infected bone.",
        "Immunocompromised hosts at increased risk",
        "Initial therapy for septic arthritis caused by Gram-negative bacilli",
        "Synovial fluid WBC > 25,000",
        "Gram-stain of synovial fluid positive for Gram-negative rods or lab reports positive culture for gram-negative bacilli---in vitro susceptibility pending",
        "Look for concomitant presence of crystals of uric acid (gout) or calcium pyrophosphate (pseudogout)",
        "Note: potential for any gram negative bacilli to produce extended spectrum beta lactamases (ESBL), carbapenemases or other mechanisms of antibiotic resistance. Need susceptibility data.",
        "Obtain blood and synovial fluid for culture.",
        "Need in vitro susceptibility data."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Escherichia coli",
        "Klebsiella pneumoniae",
        "Enterobacter and other enteric Gram-negative bacilli",
        "Pseudomonas aeruginosa",
        "Potential for any of the above to produce ESBLs or Carbapenemases"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Primary Regimens"
    },\n    {
      "type": "nestedContent",
      "content": [
        {
          "type": "header",
          "level": 2,
          "text": "Empiric Therapy"
        },
        {
          "type": "procedure",
          "procedureData": {
            "name": "Drain purulent exudate"
          }
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "appliesTo": {
              "description": "Low risk of Pseudomonas aeruginosa. Dual therapy pending culture ID"
            },
            "components": [
              {
                "drug": "Ceftriaxone",
                "dose": "2 gm",
                "route": "iv",
                "frequency": "q24h"
              },
              {
                "drug": "Levofloxacin",
                "dose": "750 mg",
                "route": "IV",
                "frequency": "q24h",
                "connector": "+"
              }
            ]
          }
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "appliesTo": {
              "description": "Risk of Pseudomonas aeruginosa. Dual therapy pending culture ID"
            },
            "components": [
              {
                "drug": "Cefepime",
                "dose": "2 gm",
                "route": "IV",
                "frequency": "q8h"
              },
              {
                "drug": "Ciprofloxacin",
                "dose": "400 mg",
                "route": "IV",
                "frequency": "q8h",
                "connector": "+"
              }
            ]
          }
        }
      ]
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "header",
          "level": 2,
          "text": "Specific/Directed Therapy"
        },
        {
          "type": "procedure",
          "procedureData": {
            "name": "Drainage of intra-articular pus by needle aspiration (repeated as needed to remove purulent exudate), arthroscopy, or arthrotomy"
          }
        },
        {
          "type": "paragraph",
          "text": "Beta-lactam or fluoroquinolone po/IV based on results of culture and susceptibility testing"
        },
        {
          "type": "paragraph",
          "text": "Duration varies with pathogenesis, host immune status and assessments of clinical response. May require up to 4 weeks of therapy"
        }
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Alternative Regimens"
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "appliesTo": {
          "description": "Skin rash \"allergy\" to penicillins and cephalosporins"
        },
        "components": [
          {
            "drug": "Ciprofloxacin",
            "dose": "400 mg",
            "route": "IV",
            "frequency": "q12h (400 mg IV q8h for P. aeruginosa)"
          },
          {
            "drug": "Levofloxacin",
            "dose": "750 mg",
            "route": "IV",
            "frequency": "q24h",
            "connector": "or"
          },
          {
            "drug": "Imipenem-cilastatin",
            "dose": "500 mg",
            "route": "IV",
            "frequency": "q6h",
            "connector": "or"
          }
        ]
      }
    },
    {
      "type": "header",
      "level": 1,
      "text": "Antimicrobial Stewardship"
    },
    {
      "type": "list",
      "items": [
        "Duration of therapy. Shorter duration (< 4 wks) may also be effective as good data on minimal duration of therapy are lacking. Suggested 4 wks is based on assumption of clinical response and normalization of WBC, CRP, procalcitonin and other biomarkers of infection.",
        "Choice of agents",
        "Empiric antibiotic should be active vs isolates with potential for antibiotic resistance. Continue empiric therapy until culture and in vitro susceptibility results are available.",
        "Specific/Directed therapy: see specific pathogens for guidance.",
        "If culture positive for Enterobacter species, avoid cephalosporins due to possible presence (estimated at up to 20%) of bacterial chromosomal inducible cephalosporosporinases (AmpC). Lab cannot routinely test for the presence of the repressed cephalosporinase (AmpC) gene.",
        "Encourage use of available molecular diagnostics, gene sequencing, mass spectroscopy to facilitate rapid microbial identification and switch from empiric to specific/directed therapy"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "Septic arthritis in children: Ped Infect Disease Journal 32: 684, 2013."
      ]
    }
  ]
}